



Docket No.: PF402P1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gentz et al.

Application No.: 09/585,541

Confirmation No.: 6732

Filed: June 2, 2000

Art Unit: 1634

For: Keratinocyte Growth Factor-2 Formulations

Examiner: B. Sisson

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

FEB 27 2004

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to reference AR32 on the attached Form PTO/SB/08. A copy of reference AR32 is enclosed.

The listed reference is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed reference of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed reference is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed document should it be applied as a reference against the claims of the subject application.

02/26/2004 HVUONG1 00000123 083425 09585541

02 FC:1806


180.00 DA

Pursuant to 37 C.F.R. § 1.97(c), because this Fourth Supplemental Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Fourth Supplemental Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent & Trademark Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the required fee, as itemized on the Fee Transmittal Sheet submitted concurrently herewith.

Dated: February 23, 2004

Respectfully submitted,

By 

Mark J. Hyman

Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-1224

MMW/MJH/KC/lcc



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/585,541-Conf. #6732
				Filing Date	June 2, 2000
				First Named Inventor	Reiner L. Gentz
				Art Unit	1634
				Examiner Name	B. L. Sisson
				Attorney Docket Number	PF402P1
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AR32	NEMA et al., "Excipients and their use in injectable products," PDA J. Pharm. Sci. & Tech. 51(4): 166-171 (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED
FEB 27 2004

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--